research A novel monilethrix mutation in coil 2A of KRT86 causing autosomal dominant monilethrix with incomplete penetrance
A new mutation in the KRT86 gene causes a hair disorder with variable expression.
Search
for
Sort by
Research
690-720 / 1000+ results
research First case of V281+I172N/V281L CYP21A2 genotype associated with congenital adrenal hyperplasia form. A case report from South Italy
New genotype linked to non-classical congenital adrenal hyperplasia found in Italian siblings.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research 丹蒽醌對人類惡性黑色素瘤細胞株(A375.S2)誘發細胞週期停滯及細胞凋亡之影響
Danthron from Rhubarb causes melanoma cells to stop growing and die.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research 51895 Interim Analysis of Platelet-Rich Plasma (PRP) Treatment for Endocrine Therapy-Induced Alopecia (EIA) and Permanent Chemotherapy-Induced Alopecia (pCIA) in Breast Cancer Patients: A Randomized Controlled Trial
PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.
research Overtreatment of Transient Maternal Hyperthyroidism Resulting in Fetal Goiter
Proper diagnosis is crucial to avoid overtreatment and complications in pregnant women with hyperthyroidism.
research 7410 Bevacizumab Induced Hypothyroidism
Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research (135) Post-Finasteride Syndrome: A Case Presentation and Discussion
research Cardiac morphologic alterations in acute minoxidil cardiotoxicity in miniature swine
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research The Effects of Photobiomodulation on MC3T3-E1 Cells via 630 nm and 810 nm Light-Emitting Diode
LED light therapy boosts bone cell growth and function.
research Rapid high-performance liquid chromatogaphic method for detection of interindividual differences in carcinogen metabolism
Human hair follicles can assess carcinogen metabolism and imidazole compounds might be effective anticarcinogens.
research Toxicity studies of iron-containing ayurvedic drug Kasisa Bhasma
Kasisa Bhasma is safer and nontoxic compared to Shodhita Kasisa.
research Modeling of ionizing radiation induced hair follicle regenerative dynamics
Hair follicles can regenerate after radiation damage but not during a specific growth phase.
research Penetration and storage of particles in human skin: Perspectives and safety aspects
Particles around 100 nm can penetrate and stay in hair follicles without passing through healthy skin, making them safe for use in topical products and useful for targeted drug delivery.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
research Faculty Opinions recommendation of Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients.
research Alopecia Areata: Pituitary Function Assessed by Assay of Pituitary Gonadotropin in Urine11From the Section of Dermatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota. The Mayo Foundation, Rochester, Minnesota, is a part of the Graduate School of the University of Minnesota.
research Platelet-Rich Plasma Resultant Cutaneous Nodules on Scalp
research BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
![Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]Fluoro-D-Glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors](/images/research/d55cf8d9-d8ee-4735-9b38-42a266b4059d/small/24322.jpg)
research Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors
FDG PET/CT scans can change cancer treatment plans for dogs.
research Activity of steroid 4 and derivatives 4a–4f as inhibitors of the enzyme 5α-reductase 1
Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
research Electronic Brachytherapy for the Treatment of Nonmelanoma Skin Cancer: Results at 3 Years
High dose rate electronic brachytherapy is an effective and safe non-surgical treatment for nonmelanoma skin cancer with good cosmetic results after three years.